-
Wearable assessment of levodopa-entacapone-carbidopa intestinal gel treatment characteristics at home: Pilot Protocol
-
Wearable Gait Metrics as Potential Digital Biomarkers in GBA1 Non-Manifesting Carriers
-
Wearable IMU-Based Gait Analysis Reveals Pharmacological Freezing-of-Gait Phenotypes in Parkinson Disease: A Longitudinal Two-Visit Study
-
Wearable Sensors Identify Mobility Features Associated With Parkinson’s Disease Years Before Clinical Diagnosis
-
Wearable-Derived Cardiac Features and Cardiac–Motor Interconnection Across Parkinson’s Disease Severities
-
Wearable-Derived Gait Biomarkers Predict Disease Severity and Quality of Life in Parkinson’s Disease: A Machine Learning and Mediation Analysis
-
Weight and Body Mass Index Changes in Parkinson’s Disease and Their Association with Disease Progression: A Two-Year Longitudinal Study
-
What Non-Genetic Parkinson’s Disease Risk Factors are Africans Exposed To? A Scoping Review
-
What two Versions of Parkinson’s „The Budget of the People“ might tell us about the Historical Background
-
When “Essential Tremor Plus” Is Not Enough: A Tremor-Dominant Presentation of Neuronal Intranuclear Inclusion Disease
-
When Motion Ceases Twice: Delayed Post-Hypoxic Leukoencephalopathy with Parkinsonism, a Case Report.
-
When Muscles Relax but Symptoms Persist: A Case of Dysfunctional Sensory-Motor Cortical Integration in Botulinum Toxin-Resistant Blepharospasm
-
When Presynaptic Stimulation is Not Enough: Severe Biphasic Dyskinesia on LECIG Reversed by Postsynaptic Apomorphine Rescue
-
When Surgical Candidates Become Ineligible: Loss of Deep Brain Stimulation Eligibility in Parkinson’s Disease — A Descriptive Study from a Brazilian Referral Center
-
White Matter Hyperintensity and the Spatial Subtypes in Parkinson’s Disease
-
Why Context Matters: The Influence of Medication and Environment on Real-World Gait in People with Parkinson’s Disease
2026 International Congress
October 4-8, 2026. Seoul, Korea.